Ann: Positive preliminary data from IHL-675A Ph 1 trial, page-6

Ok so:

-Outperformed pre-clinical and some in-vivo models versus each of the constituent substances only
-No mention of efficacy in humans during Phase I, although safety/tolerability established.

I know that Phase I is for safety primarily, so I guess we've checked the box if we're heading to Phase II. But one has to wonder why they didn't report any efficacy in the Phase I cohort? Were they simply not measuring any signals of efficacy? Or is there potential efficacy and we'll find out once the contracted organisation finishes their analyses and releases the final report?